173 related articles for article (PubMed ID: 7213514)
1. Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver.
Davies DS; Kahn GC; Murray S; Brodie MJ; Boobis AR
Br J Clin Pharmacol; 1981 Jan; 11(1):89-91. PubMed ID: 7213514
[No Abstract] [Full Text] [Related]
2. Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man.
Bertilsson L; Eichelbaum M; Mellström B; Säwe J; Schulz HU; Sjöqvist F
Life Sci; 1980 Nov; 27(18):1673-7. PubMed ID: 7442467
[No Abstract] [Full Text] [Related]
3. Deficient metabolism of debrisoquine and sparteine.
Inaba T; Otton SV; Kalow W
Clin Pharmacol Ther; 1980 Apr; 27(4):547-9. PubMed ID: 7357813
[TBL] [Abstract][Full Text] [Related]
4. Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation.
Danhof M; Idle JR; Teunissen MW; Sloan TP; Breimer DD; Smith RL
Pharmacology; 1981; 22(6):349-58. PubMed ID: 7267701
[TBL] [Abstract][Full Text] [Related]
5. The influence of changes in dietary fat on the clearance of antipyrine and 4-hydroxylation of debrisoquine.
Mucklow JC; Caraher MT; Idle JR; Rawlins MD; Sloan T; Smith RL; Wood P
Br J Clin Pharmacol; 1980 Mar; 9(3):283P. PubMed ID: 7362739
[No Abstract] [Full Text] [Related]
6. Oxidation of tricyclic antidepressant drugs, debrisoquine and 7-ethoxyresorufin, by human liver preparations.
von Bahr C; Birgersson C; Morgan ET; Eriksson O; Göransson M; Spina E; Woodhouse K
Xenobiotica; 1986 May; 16(5):391-400. PubMed ID: 3739365
[TBL] [Abstract][Full Text] [Related]
7. Polymorphic hydroxylation of debrisoquine.
Tucker GT; Silas JH; Iyun AO; Lennard MS; Smith AJ
Lancet; 1977 Oct; 2(8040):718. PubMed ID: 71525
[No Abstract] [Full Text] [Related]
8. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS
Cancer Res; 1984 Dec; 44(12 Pt 1):5692-7. PubMed ID: 6498831
[TBL] [Abstract][Full Text] [Related]
9. Bufuralol metabolism in human liver: a sensitive probe for the debrisoquine-type polymorphism of drug oxidation.
Minder EI; Meier PJ; Müller HK; Minder C; Meyer UA
Eur J Clin Invest; 1984 Jun; 14(3):184-9. PubMed ID: 6147254
[TBL] [Abstract][Full Text] [Related]
10. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
[TBL] [Abstract][Full Text] [Related]
11. Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man.
Boobis AR; Murray S; Kahn GC; Robertz GM; Davies DS
Mol Pharmacol; 1983 Mar; 23(2):474-81. PubMed ID: 6220203
[TBL] [Abstract][Full Text] [Related]
12. Lack of defect in oxidative hydroxylation of debrisoquine in a patient with halothane hepatitis.
Toutoungi M; Magnenat D
Eur J Clin Pharmacol; 1990; 38(6):633-4. PubMed ID: 2373140
[No Abstract] [Full Text] [Related]
13. Variants of human microsomal enzymes.
Davies DS; Boobis AR
Biochem Soc Trans; 1983 Aug; 11(4):459-60. PubMed ID: 6617977
[No Abstract] [Full Text] [Related]
14. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.
Otton SV; Brinn RU; Gram LF
Drug Metab Dispos; 1988; 16(1):15-7. PubMed ID: 2894945
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
Bertilsson L; Dengler HJ; Eichelbaum M; Schulz HU
Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707
[TBL] [Abstract][Full Text] [Related]
16. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation.
Meier PJ; Mueller HK; Dick B; Meyer UA
Gastroenterology; 1983 Sep; 85(3):682-92. PubMed ID: 6603386
[TBL] [Abstract][Full Text] [Related]
17. Spectral binding studies of the polymorphically metabolized drugs debrisoquine, sparteine and phenformin by cytochrome P-450 of normal and hydroxylation deficient rat strains.
Küpfer A; Al-Dabbagh SG; Ritchie JC; Idle JR; Smith RL
Biochem Pharmacol; 1982 Oct; 31(20):3193-9. PubMed ID: 7150348
[TBL] [Abstract][Full Text] [Related]
18. Correlation between nortriptyline and debrisoquine hydroxylation in the human liver.
von Bahr C; Birgersson C; Blanck A; Göransson M; Mellström B; Nilsell K
Life Sci; 1983 Aug; 33(7):631-6. PubMed ID: 6410141
[TBL] [Abstract][Full Text] [Related]
19. Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation.
Dayer P; Leemann T; Küpfer A; Kronbach T; Meyer UA
Eur J Clin Pharmacol; 1986; 31(3):313-8. PubMed ID: 2878813
[TBL] [Abstract][Full Text] [Related]
20. Antipyrine metabolism in female Lewis and Dark Agouti strains of rats, which are extensive and poor metabolizers of debrisoquine, respectively.
Tanaka E; Kobayashi S; Uchida E; Oguchi K; Yasuhara H
Jpn J Pharmacol; 1989 Mar; 49(3):433-5. PubMed ID: 2747044
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
